;PMID: 7479840
;source_file_689.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..51] = [t:0..51]
;1)sentence:[e:56..256] = [t:56..256]
;2)section:[e:260..339] = [t:260..339]
;3)section:[e:343..481] = [t:343..481]
;4)sentence:[e:485..578] = [t:485..578]
;5)sentence:[e:579..731] = [t:579..731]
;6)sentence:[e:732..840] = [t:732..840]
;7)sentence:[e:841..1152] = [t:841..1152]
;8)sentence:[e:1153..1396] = [t:1153..1396]
;9)sentence:[e:1397..1534] = [t:1397..1534]
;10)sentence:[e:1535..1673] = [t:1535..1673]
;11)sentence:[e:1674..1784] = [t:1674..1784]
;12)sentence:[e:1785..2176] = [t:1785..2176]
;13)section:[e:2180..2224] = [t:2180..2224]

;section 0 Span:0..51
;Proc Natl Acad Sci U S A  1995 Nov 7;92(23):10560-4
(SEC
  (FRAG (NNP:[0..4] Proc) (NNP:[5..9] Natl) (NNP:[10..14] Acad)
        (NNP:[15..18] Sci) (NNP:[19..20] U) (NNP:[21..22] S) (NNP:[23..24] A)
        (POS:[26..30] 1995) (NNP:[31..34] Nov) (CC:[35..40] 7;92-LRB-)
        (CD:[40..42] 23) (-RRB-:[42..43] -RRB-) (CD:[43..49] :10560)
        (::[49..50] -) (CD:[50..51] 4)))

;sentence 1 Span:56..256
;Identification of a point mutation in the catalytic domain of the
;protooncogene  c-kit in peripheral blood mononuclear cells of patients who
;have mastocytosis  with an associated hematologic disorder.
;[76..90]:variation-type:"point mutation"
;[137..142]:gene-rna:"c-kit"
;[202..255]:malignancy:"mastocytosis  with an associated hematologic
;disorder"
(SENT
  (NP-HLN
    (NP (NN:[56..70] Identification))
    (PP (IN:[71..73] of)
      (NP
        (NP (DT:[74..75] a)
           (NN:[76..81] point) (NN:[82..90] mutation))
        (PP (IN:[91..93] in)
          (NP
            (NP
              (NP (DT:[94..97] the) (JJ:[98..107] catalytic)
                  (NN:[108..114] domain))
              (PP (IN:[115..117] of)
                (NP (DT:[118..121] the) (NN:[122..135] protooncogene)
                    (NN:[137..142] c-kit))))
            (PP (IN:[143..145] in)
              (NP
                (NP
                  (NML (JJ:[146..156] peripheral) (NN:[157..162] blood))
                  (JJ:[163..174] mononuclear) (NNS:[175..180] cells))
                (PP (IN:[181..183] of)
                  (NP
                    (NP (NNS:[184..192] patients))
                    (SBAR
                      (WHNP-1 (WP:[193..196] who))
                      (S
                        (NP-SBJ-1 (-NONE-:[196..196] *T*))
                        (VP (VBP:[197..201] have)
                          (NP
                            (NP (NN:[202..214] mastocytosis))
                            (PP (IN:[216..220] with)
                              (NP (DT:[221..223] an) (VBN:[224..234] associated)
                                  (JJ:[235..246] hematologic)
                                  (NN:[247..255] disorder)))))))))))))))
    (.:[255..256] .)))

;section 2 Span:260..339
;Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe
;DD.
(SEC
  (FRAG (NNP:[260..266] Nagata) (NNP:[267..268] H) (,:[268..269] ,)
        (NNP:[270..277] Worobec) (NNP:[278..280] AS) (,:[280..281] ,)
        (NNP:[282..284] Oh) (CC:[285..287] CK) (,:[287..288] ,)
        (NNP:[289..298] Chowdhury) (NNP:[299..301] BA) (,:[301..302] ,)
        (NNP:[303..313] Tannenbaum) (NNP:[314..316] S,) (NNP:[317..323] Suzuki)
        (NNP:[324..325] Y) (,:[325..326] ,) (NNP:[327..335] Metcalfe)
        (NNP:[336..339] DD.)))

;section 3 Span:343..481
;Allergic Diseases Section, National Institute of Allergy and Infectious 
;Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
(SEC
  (FRAG (DT:[343..351] Allergic) (NNP:[352..360] Diseases)
        (NNP:[361..368] Section) (,:[368..369] ,) (NNP:[370..378] National)
        (NNP:[379..388] Institute) (IN:[389..391] of) (NNP:[392..399] Allergy)
        (CC:[400..403] and) (NNP:[404..414] Infectious)
        (NNP:[416..424] Diseases) (,:[424..425] ,) (NNP:[426..434] National)
        (NNPS:[435..445] Institutes) (IN:[446..448] of) (NNP:[449..455] Health)
        (,:[455..456] ,) (NNP:[457..465] Bethesda) (,:[465..466] ,)
        (NNP:[467..469] MD) (CD:[470..475] 20892) (,:[475..476] ,)
        (NNP:[477..480] USA) (.:[480..481] .)))

;sentence 4 Span:485..578
;Both stem cells and mast cells express c-kit and proliferate after exposure
;to  c-kit ligand.
;[524..529]:gene-rna:"c-kit"
;[565..570]:gene-generic:"c-kit"
(SENT
  (S
    (NP-SBJ (CC:[485..489] Both)
      (NP (NN:[490..494] stem) (NNS:[495..500] cells))
      (CC:[501..504] and)
      (NP (NN:[505..509] mast) (NNS:[510..515] cells)))
    (VP
      (VP (VBP:[516..523] express)
        (NP (NN:[524..529] c-kit)))
      (CC:[530..533] and)
      (VP (VBP:[534..545] proliferate))
      (PP-TMP (IN:[546..551] after)
        (NP
          (NP (NN:[552..560] exposure))
          (PP (TO:[561..563] to)
            (NP (NN:[565..570] c-kit) (NN:[571..577] ligand))))))
    (.:[577..578] .)))

;sentence 5 Span:579..731
;Mutations in c-kit may enhance or interfere with the ability of  c-kit
;receptor to initiate the intracellular pathways resulting in cell 
;proliferation.
;[592..597]:gene-rna:"c-kit"
;[644..649]:gene-protein:"c-kit"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[579..588] Mutations))
      (PP (IN:[589..591] in)
        (NP (NN:[592..597] c-kit))))
    (VP (MD:[598..601] may)
      (VP
        (VP (VB:[602..609] enhance)
          (NP-2 (-NONE-:[609..609] *RNR*)))
        (CC:[610..612] or)
        (VP (VB:[613..622] interfere)
          (PP (IN:[623..627] with)
            (NP-2 (-NONE-:[627..627] *RNR*))))
        (NP-2
          (NP (DT:[628..631] the) (NN:[632..639] ability)
            (S-1 (-NONE-:[639..639] *ICH*)))
          (PP (IN:[640..642] of)
            (NP (NN:[644..649] c-kit) (NN:[650..658] receptor)))
          (S-1
            (NP-SBJ (-NONE-:[658..658] *))
            (VP (TO:[659..661] to)
              (VP (VB:[662..670] initiate)
                (NP
                  (NP (DT:[671..674] the) (JJ:[675..688] intracellular)
                      (NNS:[689..697] pathways))
                  (VP (VBG:[698..707] resulting)
                    (PP-CLR (IN:[708..710] in)
                      (NP (NN:[711..715] cell) (NN:[717..730] proliferation)))))))))))
    (.:[730..731] .)))

;sentence 6 Span:732..840
;These observations suggested to us that mastocytosis might in  some patients
;result from mutations in c-kit.
;[772..784]:malignancy:"mastocytosis"
;[834..839]:gene-rna:"c-kit"
(SENT
  (S
    (NP-SBJ (DT:[732..737] These) (NNS:[738..750] observations))
    (VP (VBD:[751..760] suggested)
      (PP (TO:[761..763] to)
        (NP (PRP:[764..766] us)))
      (SBAR (IN:[767..771] that)
        (S
          (NP-SBJ (NN:[772..784] mastocytosis))
          (VP (MD:[785..790] might)
            (PP-LOC (IN:[791..793] in)
              (NP (DT:[795..799] some) (NNS:[800..808] patients)))
            (VP (VBP:[809..815] result)
              (PP-CLR (IN:[816..820] from)
                (NP
                  (NP (NNS:[821..830] mutations))
                  (PP-LOC (IN:[831..833] in)
                    (NP (NN:[834..839] c-kit))))))))))
    (.:[839..840] .)))

;sentence 7 Span:841..1152
;cDNA synthesized from peripheral  blood mononuclear cells of patients with
;indolent mastocytosis, mastocytosis  with an associated hematologic disorder,
;aggressive mastocytosis, solitary  mastocytoma, and chronic myelomonocytic
;leukemia unassociated with mastocytosis  was thus screened for a mutation of
;c-kit.
;[916..937]:malignancy:"indolent mastocytosis"
;[939..992]:malignancy:"mastocytosis  with an associated hematologic
;disorder"
;[994..1017]:malignancy:"aggressive mastocytosis"
;[1019..1040]:malignancy:"solitary  mastocytoma"
;[1046..1108]:malignancy:"chronic myelomonocytic leukemia unassociated with
;mastocytosis"
;[1146..1151]:gene-rna:"c-kit"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[841..845] cDNA))
      (VP (VBN:[846..857] synthesized)
        (NP (-NONE-:[857..857] *))
        (PP (IN:[858..862] from)
          (NP
            (NP
              (NML (JJ:[863..873] peripheral) (NN:[875..880] blood))
              (JJ:[881..892] mononuclear) (NNS:[893..898] cells))
            (PP (IN:[899..901] of)
              (NP
                (NP (NNS:[902..910] patients))
                (PP (IN:[911..915] with)
                  (NP
                    (NP (JJ:[916..924] indolent) (NN:[925..937] mastocytosis))
                    (,:[937..938] ,)
                    (NP
                      (NP (NN:[939..951] mastocytosis))
                      (PP (IN:[953..957] with)
                        (NP (DT:[958..960] an) (VBN:[961..971] associated)
                            (JJ:[972..983] hematologic) (NN:[984..992] disorder))))
                    (,:[992..993] ,)
                    (NP (JJ:[994..1004] aggressive)
                        (NN:[1005..1017] mastocytosis))
                    (,:[1017..1018] ,)
                    (NP (JJ:[1019..1027] solitary) (NN:[1029..1040] mastocytoma))
                    (,:[1040..1041] ,) (CC:[1042..1045] and)
                    (NP
                      (NP (JJ:[1046..1053] chronic)
                          (JJ:[1054..1068] myelomonocytic)
                          (NN:[1069..1077] leukemia))
                      (ADJP (JJ:[1078..1090] unassociated)
                        (PP (IN:[1091..1095] with)
                          (NP (NN:[1096..1108] mastocytosis)))))))))))))
    (VP (VBD:[1110..1113] was)
      (ADVP (RB:[1114..1118] thus))
      (VP (VBN:[1119..1127] screened)
        (NP-1 (-NONE-:[1127..1127] *))
        (PP (IN:[1128..1131] for)
          (NP
            (NP (DT:[1132..1133] a) (NN:[1134..1142] mutation))
            (PP (IN:[1143..1145] of)
              (NP (NN:[1146..1151] c-kit)))))))
    (.:[1151..1152] .)))

;sentence 8 Span:1153..1396
;This analysis revealed that four of  four mastocytosis patients with an
;associated hematologic disorder with  predominantly myelodysplastic features
;had an A-->T substitution at nt 2468 of  c-kit mRNA that causes an
;Asp-816-->Val substitution.
;[1195..1256]:malignancy:"mastocytosis patients with an associated hematologic
;disorder"
;[1309..1310]:variation-state-original:"A"
;[1313..1314]:variation-state-altered:"T"
;[1315..1327]:variation-type:"substitution"
;[1331..1338]:variation-location:"nt 2468"
;[1343..1348]:gene-rna:"c-kit"
;[1369..1372]:variation-state-original:"Asp"
;[1373..1376]:variation-location:"816"
;[1379..1382]:variation-state-altered:"Val"
;[1383..1395]:variation-type:"substitution"
(SENT
  (S
    (NP-SBJ (DT:[1153..1157] This) (NN:[1158..1166] analysis))
    (VP (VBD:[1167..1175] revealed)
      (SBAR (IN:[1176..1180] that)
        (S
          (NP-SBJ
            (NP (CD:[1181..1185] four))
            (PP (IN:[1186..1188] of)
              (NP
                (NP (CD:[1190..1194] four) (NN:[1195..1207] mastocytosis)
                    (NNS:[1208..1216] patients))
                (PP (IN:[1217..1221] with)
                  (NP
                    (NP (DT:[1222..1224] an) (VBN:[1225..1235] associated)
                        (JJ:[1236..1247] hematologic) (NN:[1248..1256] disorder))
                    (PP (IN:[1257..1261] with)
                      (NP (RB:[1263..1276] predominantly)
                          (JJ:[1277..1292] myelodysplastic)
                          (NNS:[1293..1301] features))))))))
          (VP (VBD:[1302..1305] had)
            (NP
              (NP
                (NP (DT:[1306..1308] an)
                  (NML
                    (NML (NN:[1309..1310] A))
                    (PP (SYM:[1310..1313] -->)
                      (NP (NN:[1313..1314] T))))
                  (NN:[1315..1327] substitution))
                (PP-LOC (IN:[1328..1330] at)
                  (NP
                    (NP (NN:[1331..1333] nt) (CD:[1334..1338] 2468))
                    (PP (IN:[1339..1341] of)
                      (NP (NN:[1343..1348] c-kit) (NN:[1349..1353] mRNA))))))
              (SBAR
                (WHNP-1 (WDT:[1354..1358] that))
                (S
                  (NP-SBJ-1 (-NONE-:[1358..1358] *T*))
                  (VP (VBZ:[1359..1365] causes)
                    (NP (DT:[1366..1368] an)
                      (NML
                        (NML (NN:[1369..1372] Asp) (HYPH:[1372..1373] -)
                             (CD:[1373..1376] 816))
                        (PP (SYM:[1376..1379] -->)
                          (NP (NN:[1379..1382] Val))))
                      (NN:[1383..1395] substitution))))))))))
    (.:[1395..1396] .)))

;sentence 9 Span:1397..1534
;One of one patient  examined who had mastocytosis with an associated
;hematologic disorder had the  corresponding mutation in genomic DNA.
;[1434..1486]:malignancy:"mastocytosis with an associated hematologic
;disorder"
;[1510..1518]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1397..1400] One))
      (PP (IN:[1401..1403] of)
        (NP
          (NP
            (NP (CD:[1404..1407] one) (NN:[1408..1415] patient))
            (VP (VBN:[1417..1425] examined)
              (NP (-NONE-:[1425..1425] *))))
          (SBAR
            (WHNP-1 (WP:[1426..1429] who))
            (S
              (NP-SBJ-1 (-NONE-:[1429..1429] *T*))
              (VP (VBD:[1430..1433] had)
                (NP
                  (NP (NN:[1434..1446] mastocytosis))
                  (PP (IN:[1447..1451] with)
                    (NP (DT:[1452..1454] an) (VBN:[1455..1465] associated)
                        (JJ:[1466..1477] hematologic) (NN:[1478..1486] disorder))))))))))
    (VP (VBD:[1487..1490] had)
      (NP
        (NP (DT:[1491..1494] the) (VBG:[1496..1509] corresponding)
            (NN:[1510..1518] mutation))
        (PP (IN:[1519..1521] in)
          (NP (JJ:[1522..1529] genomic) (NN:[1530..1533] DNA)))))
    (.:[1533..1534] .)))

;sentence 10 Span:1535..1673
;Identical or similar amino acid  substitutions in mast cell lines result in
;ligand-independent  autophosphorylation of the c-kit receptor.
;[1556..1581]:variation-type:"amino acid  substitutions"
;[1658..1663]:gene-protein:"c-kit"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[1535..1544] Identical)
          (NML-1 (-NONE-:[1544..1544] *P*)))
        (CC:[1545..1547] or)
        (NP (JJ:[1548..1555] similar)
          (NML-1 (JJ:[1556..1561] amino) (NN:[1562..1566] acid)
                 (NNS:[1568..1581] substitutions))))
      (PP (IN:[1582..1584] in)
        (NP (NN:[1585..1589] mast) (NN:[1590..1594] cell)
            (NNS:[1595..1600] lines))))
    (VP (VBP:[1601..1607] result)
      (PP-CLR (IN:[1608..1610] in)
        (NP
          (NP
            (ADJP (NN:[1611..1617] ligand) (HYPH:[1617..1618] -)
                  (JJ:[1618..1629] independent))
            (NN:[1631..1650] autophosphorylation))
          (PP (IN:[1651..1653] of)
            (NP (DT:[1654..1657] the) (NN:[1658..1663] c-kit)
                (NN:[1664..1672] receptor))))))
    (.:[1672..1673] .)))

;sentence 11 Span:1674..1784
;This mutation was not identified in  the patients within the other disease
;categories or in 67 of 67 controls.
;[1679..1687]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ-1 (DT:[1674..1678] This) (NN:[1679..1687] mutation))
    (VP (VBD:[1688..1691] was) (RB:[1692..1695] not)
      (VP (VBN:[1696..1706] identified)
        (NP-1 (-NONE-:[1706..1706] *))
        (PP
          (PP-LOC (IN:[1707..1709] in)
            (NP
              (NP (DT:[1711..1714] the) (NNS:[1715..1723] patients))
              (PP (IN:[1724..1730] within)
                (NP (DT:[1731..1734] the) (JJ:[1735..1740] other)
                    (NN:[1741..1748] disease) (NNS:[1749..1759] categories)))))
          (CC:[1760..1762] or)
          (PP (IN:[1763..1765] in)
            (NP
              (NP (CD:[1766..1768] 67))
              (PP (IN:[1769..1771] of)
                (NP (CD:[1772..1774] 67) (NNS:[1775..1783] controls))))))))
    (.:[1783..1784] .)))

;sentence 12 Span:1785..2176
;The  identification of the point mutation Asp816Val in c-kit in patients with
; mastocytosis with an associated hematologic disorder provides insight not
;only  into the pathogenesis of this form of mastocytosis but also into how 
;hematopoiesis may become dysregulated and may serve to provide a means of 
;confirming the diagnosis, assessing prognosis, and developing intervention 
;strategies.
;[1812..1826]:variation-type:"point mutation"
;[1827..1830]:variation-state-original:"Asp"
;[1830..1833]:variation-location:"816"
;[1833..1836]:variation-state-altered:"Val"
;[1840..1845]:gene-rna:"c-kit"
;[1864..1916]:malignancy:"mastocytosis with an associated hematologic
;disorder"
;[1982..1994]:malignancy:"mastocytosis"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1785..1788] The) (NN:[1790..1804] identification))
      (PP (IN:[1805..1807] of)
        (NP
          (NP (DT:[1808..1811] the)
             (NN:[1812..1817] point) (NN:[1818..1826] mutation))
          (NP (NN:[1827..1830] Asp) (CD:[1830..1833] 816) (NN:[1833..1836] Val))))
      (PP (IN:[1837..1839] in)
        (NP
          (NP (NN:[1840..1845] c-kit))
          (PP-LOC (IN:[1846..1848] in)
            (NP
              (NP (NNS:[1849..1857] patients))
              (PP (IN:[1858..1862] with)
                (NP
                  (NP (NN:[1864..1876] mastocytosis))
                  (PP (IN:[1877..1881] with)
                    (NP (DT:[1882..1884] an) (VBN:[1885..1895] associated)
                        (JJ:[1896..1907] hematologic) (NN:[1908..1916] disorder))))))))))
    (VP
      (VP (VBZ:[1917..1925] provides)
        (NP (NN:[1926..1933] insight))
        (PP
          (CONJP (RB:[1934..1937] not) (RB:[1938..1942] only))
          (PP (IN:[1944..1948] into)
            (NP
              (NP (DT:[1949..1952] the) (NN:[1953..1965] pathogenesis))
              (PP (IN:[1966..1968] of)
                (NP
                  (NP (DT:[1969..1973] this) (NN:[1974..1978] form))
                  (PP (IN:[1979..1981] of)
                    (NP (NN:[1982..1994] mastocytosis)))))))
          (CONJP (CC:[1995..1998] but) (RB:[1999..2003] also))
          (PP (IN:[2004..2008] into)
            (SBAR-NOM (WRB:[2009..2012] how)
              (S
                (NP-SBJ (NN:[2014..2027] hematopoiesis))
                (VP (MD:[2028..2031] may)
                  (VP (VB:[2032..2038] become)
                    (NP-PRD (JJ:[2039..2051] dysregulated)))))))))
      (CC:[2052..2055] and)
      (VP (MD:[2056..2059] may)
        (VP (VB:[2060..2065] serve)
          (S
            (NP-SBJ (-NONE-:[2065..2065] *))
            (VP (TO:[2066..2068] to)
              (VP (VB:[2069..2076] provide)
                (NP
                  (NP (DT:[2077..2078] a) (NN:[2079..2084] means))
                  (PP (IN:[2085..2087] of)
                    (S-NOM
                      (NP-SBJ (-NONE-:[2087..2087] *))
                      (VP
                        (VP (VBG:[2089..2099] confirming)
                          (NP (DT:[2100..2103] the) (NN:[2104..2113] diagnosis)))
                        (,:[2113..2114] ,)
                        (VP (VBG:[2115..2124] assessing)
                          (NP (NN:[2125..2134] prognosis)))
                        (,:[2134..2135] ,) (CC:[2136..2139] and)
                        (VP (VBG:[2140..2150] developing)
                          (NP (NN:[2151..2163] intervention)
                              (NNS:[2165..2175] strategies)))))))))))))
    (.:[2175..2176] .)))

;section 13 Span:2180..2224
;PMID: 7479840 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2180..2184] PMID) (::[2184..2185] :) (CD:[2186..2193] 7479840)
        (NN:[2194..2195] -LSB-) (NNP:[2195..2201] PubMed) (::[2202..2203] -)
        (NN:[2204..2211] indexed) (IN:[2212..2215] for)
        (NNP:[2216..2224] MEDLINE-RSB-)))
